Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucel gambiense: A randomised trial

Lancet

Volumn 355, Issue 9213, 2000, Pages 1419-1425

  Burri, C ^a   Nkunku, S ^a   Merolle, A ^b   Smith, T ^a   Blum, J ^a   Brun, R ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Norwegians Peoples Aid   (Angola)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; MEBENDAZOLE; MELARSOPROL; MULTIVITAMIN; PARACETAMOL; PREDNISOLONE;

ABDOMINAL PAIN; AFRICAN TRYPANOSOMIASIS; ANGOLA; ARTICLE; BRAIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EXFOLIATIVE DERMATITIS; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; POLYNEUROPATHY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; THORAX PAIN; TREATMENT OUTCOME; TRYPANOSOMA;

EID: 0034701571     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02141-3     Document Type: Article

References (26)

1. Smith D.H., Pepin J., Stich A.H. Human African trypanosomiasis. an emerging public health crisis Br Med Bull. 54:1998;341-355.
2. Ekwanzala M., Pepin J., Khonde N., Molisho S., Bruneel H., De Wals P. In the heart of darkness. sleeping sickness in Zaire Lancet. 348:1996;1427-1430.
3. Control and surveillance of African trypanosomiasis. WHO Tech Rep Ser. 881( i-vi):1998;1-114.
4. Friedheim E.A.H. Mel B in the treatment of human trypanosomiasis. Am J Trop Med Hyg. 29:1949;173-180.
5. Pepin J., Milord F. The treatment of human African trypanosomiasis. Adv Parasitol. 33:1994;1-47.
6. Burri C., Giroud C., Doua F., Welker H.A., Brun R. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy. 39:1993;225-234.
7. Burri C., Onyango J.D., Auma J.E., Burudi E.M., Brun R. Pharmacokinetics of melarsoprol in uninfected vervet monkeys. Acta Trop. 58:1994;35-49.
8. Burri C., Blum J., Brun R. Alternative application of melarsoprol for treatment of Tb gambiense sleeping sickness. preliminary results Ann Soc Belg Med Trop. 75:1995;65-71.
9. Magnus E., Vervoort T., Van Meirvenne N. A card agglutination test with stained trypanosomes (CATT) for the serological diagnosis of Tb gambiense trypanosomiaisis. Ann Soc Belg Med Trop. 58:1978;169-176.
10. Farrington C.P., Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 9:1990;1447-1454.
11. Roebruck P., Kühn A. Comparison of tests and sample size formulae for proving therapeutic equivalence based on the difference of bionomial probabilities. Stat Med. 14:1995;1583-1594.
12. Duke B.O.L. A fatality during treatment of onchocerciasis with Mel W. Trans R Soc Trop Med Hyg. 60:1966;691-692.
13. Ferreira M.S., Nishioka S.d.A., Silvestre M.T., Borges A.S., Nunes-Araujo F.R., Rocha A. Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis. 25:1997;1397-1400.
14. Alvar J., Canavate C., Gutierrez-Solar B.et al. Leishmania and human immunodeficiency virus coinfection. the first 10 years Clin Microbiol Rev. 10:1997;298-319.
15. Hunter C.A., Jennings F.W., Adams J.H., Murray M., Kennedy P.G.E. Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis. Lancet. 339:1992;956-958.
16. Jennings F.W., Hunter C.A., Kennedy P.G.E., Murray M. Chemotherapy of Trupanosoma brucei infection of the central nervous system. the use of a rapid chemotherapeutic regimen and the development of post-treatment encephalopathies Trans R Soc Trop Med Hyg. 87:1993;224-226.
17. Veiga Fernandes J.H., Atouguia J.M., Peleteiro M.C., Jenniings F.W., Rosario V.E. Post-treatment hind-leg paralysis in mice infected with Trypanosoma brucei brucei. a light microscopic study Acta Trop. 63:1997;179-184.
18. Ancelle T., Barret B., Flachet L., Moren A. [Two epidemics of arsenical encephalopathy in the treatment of trypanosomiasis, Uganda, 1992-1991]. Bull Soc Pathol Exot. 87:1994;341-346.
19. Gherardi R.K., Chariot P., Vanderstigel M.et al. Organic arsenic-induced Guillain-Barré-like syndrome due to melarsoprol. a clinical, electrophysiological, and pathological study Muscle Nerve. 13:1990;637-645.
20. Doua F., Yapo F.B. Human trypanosomiasis in the Ivory Coast - therapy and problems. Acta Trop. 54:1993;163-168.
21. Wang C.C. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol. 35:1995;93-127.
22. Croft S.L., Urbina J.A., Brun R. Chemotherapy of human leishmaniasis and trypanosomiasis. Hide G., Mottram J.C., Coombs G.H., Holmes P.H. Trypanosomiasis and leishmaniasis. 1997;245-257 CAB International, Wallingford.
23. Sjoerdsma A., Schechter P.J. Eflornithine for African sleeping sickness. Lancet. 354:1999;254.
24. Burri C., Brun R. An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid. Trop Med Parasitol. 43:1992;223-225.
25. Bronner U., Brun R., Doua F.et al. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T gambiense sleeping sickness indicates that melarsoprol is metabolized. Trop Med Int Health. 3:1998;913-917.
26. Pepin J., Milord F., Khonde A., Niyonsenga T., Loko L., Mpia B. Gambiense trypanosomiasis. frequency of, and risk factors for, failure of melarsoprol therapy Trans R Soc Trop Med Hyg. 88:1994;447-452.